Regeneron Pharmaceuticals (REGN) Total Debt (2020 - 2025)
Historic Total Debt for Regeneron Pharmaceuticals (REGN) over the last 6 years, with Q4 2025 value amounting to $2.0 billion.
- Regeneron Pharmaceuticals' Total Debt rose 7.56% to $2.0 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $2.0 billion, marking a year-over-year increase of 7.56%. This contributed to the annual value of $2.0 billion for FY2025, which is 7.56% up from last year.
- According to the latest figures from Q4 2025, Regeneron Pharmaceuticals' Total Debt is $2.0 billion, which was up 7.56% from $2.0 billion recorded in Q3 2025.
- Regeneron Pharmaceuticals' 5-year Total Debt high stood at $2.0 billion for Q3 2025, and its period low was $2.0 billion during Q1 2021.
- For the 5-year period, Regeneron Pharmaceuticals' Total Debt averaged around $2.0 billion, with its median value being $2.0 billion (2023).
- Within the past 5 years, the most significant YoY rise in Regeneron Pharmaceuticals' Total Debt was 3194.67% (2021), while the steepest drop was 6.57% (2021).
- Over the past 5 years, Regeneron Pharmaceuticals' Total Debt (Quarter) stood at $2.0 billion in 2021, then grew by 0.07% to $2.0 billion in 2022, then increased by 0.08% to $2.0 billion in 2023, then increased by 0.08% to $2.0 billion in 2024, then rose by 0.08% to $2.0 billion in 2025.
- Its Total Debt was $2.0 billion in Q4 2025, compared to $2.0 billion in Q3 2025 and $2.0 billion in Q2 2025.